155 related articles for article (PubMed ID: 27642077)
1. Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder.
Frick A; Åhs F; Appel L; Jonasson M; Wahlstedt K; Bani M; Merlo Pich E; Bettica P; Långström B; Lubberink M; Fredrikson M; Furmark T
Eur Neuropsychopharmacol; 2016 Nov; 26(11):1775-1783. PubMed ID: 27642077
[TBL] [Abstract][Full Text] [Related]
2. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
Furmark T; Appel L; Michelgård A; Wahlstedt K; Ahs F; Zancan S; Jacobsson E; Flyckt K; Grohp M; Bergström M; Pich EM; Nilsson LG; Bani M; Långström B; Fredrikson M
Biol Psychiatry; 2005 Jul; 58(2):132-42. PubMed ID: 16038684
[TBL] [Abstract][Full Text] [Related]
3. Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial.
Faria V; Gingnell M; Hoppe JM; Hjorth O; Alaie I; Frick A; Hultberg S; Wahlstedt K; Engman J; Månsson KNT; Carlbring P; Andersson G; Reis M; Larsson EM; Fredrikson M; Furmark T
EBioMedicine; 2017 Oct; 24():179-188. PubMed ID: 29033138
[TBL] [Abstract][Full Text] [Related]
4. Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder.
Faria V; Appel L; Åhs F; Linnman C; Pissiota A; Frans Ö; Bani M; Bettica P; Pich EM; Jacobsson E; Wahlstedt K; Fredrikson M; Furmark T
Neuropsychopharmacology; 2012 Sep; 37(10):2222-32. PubMed ID: 22617357
[TBL] [Abstract][Full Text] [Related]
5. Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder.
Faria V; Ahs F; Appel L; Linnman C; Bani M; Bettica P; Pich EM; Wahlstedt K; Fredrikson M; Furmark T
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1149-57. PubMed ID: 24666527
[TBL] [Abstract][Full Text] [Related]
6. Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial.
Hjorth OR; Frick A; Gingnell M; Hoppe JM; Faria V; Hultberg S; Alaie I; Månsson KNT; Rosén J; Reis M; Wahlstedt K; Jonasson M; Lubberink M; Antoni G; Fredrikson M; Furmark T
Transl Psychiatry; 2021 Nov; 11(1):559. PubMed ID: 34732695
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder.
Warwick JM; Carey P; Van der Linden G; Prinsloo C; Niehaus D; Seedat S; Dupont P; Stein DJ
Metab Brain Dis; 2006 Sep; 21(2-3):241-52. PubMed ID: 16850261
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
Gobert A; Brocco M; Dekeyne A; Di Cara B; Bouchez G; Lejeune F; Gannon RL; Millan MJ
Neuropsychopharmacology; 2009 Mar; 34(4):1039-56. PubMed ID: 18830239
[TBL] [Abstract][Full Text] [Related]
9. Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy.
Hjorth O; Frick A; Gingnell M; Engman J; Björkstrand J; Faria V; Alaie I; Carlbring P; Andersson G; Jonasson M; Lubberink M; Antoni G; Reis M; Wahlstedt K; Fredrikson M; Furmark T
Transl Psychiatry; 2022 Oct; 12(1):436. PubMed ID: 36202797
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.
Baldwin DS; Asakura S; Koyama T; Hayano T; Hagino A; Reines E; Larsen K
Eur Neuropsychopharmacol; 2016 Jun; 26(6):1062-9. PubMed ID: 26971233
[TBL] [Abstract][Full Text] [Related]
11. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy.
Furmark T; Tillfors M; Marteinsdottir I; Fischer H; Pissiota A; Långström B; Fredrikson M
Arch Gen Psychiatry; 2002 May; 59(5):425-33. PubMed ID: 11982446
[TBL] [Abstract][Full Text] [Related]
12. Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor.
Izumi T; Inoue T; Kitaichi Y; Nakagawa S; Koyama T
Eur J Pharmacol; 2006 Mar; 534(1-3):129-32. PubMed ID: 16494863
[TBL] [Abstract][Full Text] [Related]
13. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[11C]methyl-L-tryptophan PET study.
Berney A; Nishikawa M; Benkelfat C; Debonnel G; Gobbi G; Diksic M
Neurochem Int; 2008; 52(4-5):701-8. PubMed ID: 17928105
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials.
Hedges DW; Brown BL; Shwalb DA; Godfrey K; Larcher AM
J Psychopharmacol; 2007 Jan; 21(1):102-11. PubMed ID: 16714326
[TBL] [Abstract][Full Text] [Related]
15. [Neurobiology and pharmacotherapy of social phobia].
Aouizerate B; Martin-Guehl C; Tignol J
Encephale; 2004; 30(4):301-13. PubMed ID: 15538306
[TBL] [Abstract][Full Text] [Related]
16. Within-session effect of repeated stress exposure on extinction circuitry function in social anxiety disorder.
Åhs F; Gingnell M; Furmark T; Fredrikson M
Psychiatry Res Neuroimaging; 2017 Mar; 261():85-90. PubMed ID: 28167379
[TBL] [Abstract][Full Text] [Related]
17. Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171.
Frick A; Ahs F; Linnman C; Jonasson M; Appel L; Lubberink M; Långström B; Fredrikson M; Furmark T
Transl Psychiatry; 2015 Jul; 5(7):e597. PubMed ID: 26151925
[TBL] [Abstract][Full Text] [Related]
18. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
[TBL] [Abstract][Full Text] [Related]
19. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
Carey PD; Warwick J; Niehaus DJ; van der Linden G; van Heerden BB; Harvey BH; Seedat S; Stein DJ
BMC Psychiatry; 2004 Oct; 4():30. PubMed ID: 15482603
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
